- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02874144
Anti-Inflammatory Agent in Sinusitis (E1416)
A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2a, single-center, randomized, placebo-controlled, double-blind study that includes 12 weeks of treatment with experimental drug anti-inflammatory agent or placebo TID administered orally.
All subjects will be ≥18 years, have sinusitis with persistent symptoms despite standard of care treatment, and have failed a course of steroids in the past.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Females must have a negative urine pregnancy test at screening unless documented to have a hysterectomy or be postmenopausal.
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- Use of any investigational drugs within 30 days of screening.
- Acute infection needing antibiotic treatment at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZ Compound
40 mg 12 weeks TID po
|
40 mg three times daily po for 12 weeks
collection of biomarkers for analysis of nasal disease
Other Names:
QD Nasal Spray
Other Names:
|
Placebo Comparator: Placebo
40 mg 12 weeks TID po
|
collection of biomarkers for analysis of nasal disease
Other Names:
QD Nasal Spray
Other Names:
looks like AZ compound, made by same company, double blind.
40 mg three times daily po for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TOTAL POLYP SCORE (TPS)
Time Frame: Baseline and Week 12
|
Measure Description: Measurement of Primary outcome- 0-4 scale in each nostril, total is 8. The total polyp score is the sum of the right and left nasal polyp score. Maximum is 8, minimum is 0. Higher score indicates worse disease. 0 =No polyps 1=Small polyps in the middle meatus not reaching below the inferior border of the middle turbinate 2=Polyps reaching the lower border of the middle turbinate or polyp medial to the middle turbinate 3 = Large polyps reaching the lower border of the inferior turbinate 4 =Large polyps causing complete obstruction. The primary outcome measured change in polyp size and secondary outcomes included change in radiographic severity of sinus disease, quality of life, and nasal symptoms as measured by Sino Nasal Outcome Test-22 (SNOT-22) and sense of smell by Brief Smell Identification Test (B-SIT) at 12 weeks in the AZD1981 group vs. the placebo. These were done at the baseline visit and the Week 12 visit. |
Baseline and Week 12
|
Sinus CT Scan Scores by Lund-Mackay Scores
Time Frame: Baseline and Week 12
|
Measurement of secondary outcome: sinus CT scan scores by Lund-Mckay scores.
We measured sinus radiographic severity with Lund-Mackay scores of 0 to 24. 0 was the least severe and 24 was the most severe.
This secondary outcomes included change in radiographic severity of sinus disease, as measured by sinus CT scan scores at baseline and 12 weeks in the AZD1981 group vs. the placebo group.
|
Baseline and Week 12
|
BSIT (Brief Smell Identification Test)
Time Frame: Baseline and Week 12
|
Measurement of secondary outcome- BSIT (brief smell identification test) is a 12-item test measuring sense of smell. This is a multiple choice test with one correct answer out of four possible answer choices. This test features distinct types of smells. Minimum score: 0/12, which indicates that none of the correct answers were chosen on the 12-item test. Maximum score: 12/12, which indicates that all of the correct answers were chosen on the 12-item test. The higher the score, the better the outcome. Only one out of the four possible answer choices for each multiple choice question is correct. There are no subscales. This secondary outcome measures sense of smell by Brief Smell Identification Test (B-SIT) at baseline (visit 1) and 12 weeks (visit 5) in the AZD1981 group vs. the placebo group. |
Baseline and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SNOT-22 (Sino-Nasal Outcome Test-22) Score
Time Frame: Baseline and Week 12
|
Measurement of secondary outcome- the SNOT-22 test contains 22 items regarding patient-reported outcomes of sino-nasal symptom severity on a 0-5 scale for each item. 0 is no problem and 5 is problem as bad as it can be, so higher values represent a worse outcome than lower values. The subscale is 0 - 5 of each of the 22 items and the total score is the sum of the subscales of all 22 items. The minimum total score is 0/110. The maximum total score is 110/110. This secondary outcome measured change in patient-reported outcomes of nasal symptoms as measured by Sino Nasal Outcome Test-22 (SNOT-22) over 12 weeks in the AZD1981 group vs. the placebo group. |
Baseline and Week 12
|
Visual Analog Scale (VAS)
Time Frame: Baseline and Week 12
|
Measurement of secondary outcome- 0 to 10 scale bilaterally that measures how subjective sinus symptom severity, with 0 being the least troublesome to 10 being the most troublesome over 12 weeks in the AZD1981 group vs. the placebo group.
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anju T Peters, MD, Northwestern University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Pathological Conditions, Anatomical
- Paranasal Sinus Diseases
- Nose Diseases
- Polyps
- Sinusitis
- Nasal Polyps
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Fluticasone
- Mometasone Furoate
Other Study ID Numbers
- E1416 Sinus
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasal Polyps
-
Poitiers University HospitalRecruiting
-
GB001, Inc, a wholly owned subsidiary of Gossamer...CompletedChronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)United States, Czechia, Ukraine
-
Medical University of ViennaRecruitingChronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsAustria
-
Ohio State UniversityActive, not recruitingChronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsUnited States
-
Johns Hopkins UniversityGlaxoSmithKlineTerminatedPatients With Nasal Polyps
-
Optinose US Inc.CompletedBilateral Nasal PolyposisUnited States
-
Centre hospitalier de l'Université de Montréal...RecruitingChronic Rhinosinusitis With Nasal PolypsCanada
-
SanofiRegeneron PharmaceuticalsCompletedChronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)Belgium, Mexico, Turkey, Israel, Spain, Sweden, Argentina, Canada, Japan, United States, Australia, Chile, Portugal, Russian Federation
-
St. Paul's Sinus CentreRecruitingAsthma | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsCanada
-
Christiane HaaseActive, not recruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsDenmark
Clinical Trials on AZ compound
-
University of Alabama at BirminghamAstraZenecaTerminatedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States
-
Azafaros A.G.Active, not recruitingNiemann-Pick Disease, Type C | GM2 GangliosidosisBrazil
-
Alexza Pharmaceuticals, Inc.CelerionCompleted
-
Alexza Pharmaceuticals, Inc.CelerionCompleted
-
King Hussein Cancer CenterWithdrawn
-
Chinese PLA General HospitalCompletedBreast Neoplasms | Lung NeoplasmsChina
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, GermanyActive, not recruitingSoft-tissue SarcomaUnited Kingdom
-
Arafat TfayliMerck KGaA, Darmstadt, Germany; Phoenix Clinical ResearchUnknownNon-Small Cell Lung Cancer StageLebanon, Jordan
-
Imperial College LondonBritish Heart FoundationRecruitingDilated CardiomyopathyUnited Kingdom
-
CeleCor TherapeuticsDiagram B.V.; ST. Antonius hospital NieuwegeinCompletedMyocardial Infarction | Heart Diseases | Vascular Diseases | Coronary Disease | STEMI - ST Elevation Myocardial InfarctionNetherlands